(Total Views: 1087)
Posted On: 09/19/2017 5:19:19 PM
Post# of 229
NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Retains Consulting Services of Ben Paterson
Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced that it has retained the consulting services of Ben Paterson, P.E., to assist in defining the pathway for scale-up, purification and manufacturing strategies related to the company’s cannabinoid biosynthesis program. Paterson brings nearly four decades of experience in developing pharmaceutical manufacturing and purification processes to the InMed team, having previously served as a senior engineering advisor with Pharmaceutical giant Eli Lilly and Company for nearly four decades. “Mr. Paterson brings significant experience in all facets of biosynthesis manufacturing and facility design,” Eric A. Adams, president and CEO of InMed, stated in the news release. “His expertise directing complex capital projects, overseeing facilities and equipment, and interfacing with various stakeholders will be a significant asset to InMed.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced that it has retained the consulting services of Ben Paterson, P.E., to assist in defining the pathway for scale-up, purification and manufacturing strategies related to the company’s cannabinoid biosynthesis program. Paterson brings nearly four decades of experience in developing pharmaceutical manufacturing and purification processes to the InMed team, having previously served as a senior engineering advisor with Pharmaceutical giant Eli Lilly and Company for nearly four decades. “Mr. Paterson brings significant experience in all facets of biosynthesis manufacturing and facility design,” Eric A. Adams, president and CEO of InMed, stated in the news release. “His expertise directing complex capital projects, overseeing facilities and equipment, and interfacing with various stakeholders will be a significant asset to InMed.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
